Tresiba Solid As Novo Nordisk Plots Japan Growth
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk has had its best year ever in sales terms in Japan, where its subsidiary is benefiting mainly from the strong performance of basal insulin preparation Tresiba.